Wegovy prescribing information sheet WEGOVY. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. Wegovy ® is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. Read this Instructions for Use before you start using WEGOVY. 5 years (41. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. What is Wegovy™? Wegovy™ (semaglutide) injection 2. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for Prescribing Information & Safety Data Sheets Submit a Question Search the Exchange. 4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. 2-clean Page 1 of 35 AusPAR - Wegovy - semaglutide - PM-2022-04980-1-5 - Novo Nordisk Pty LtdDate of Finalisation 4 September 2024. 4 mg. Your Coach can help you: Get off to a good start with Wegovy ® by offering guidance and sharing tips; Find information about insurance coverage and Wegovy ® savings ; Set achievable goals and take Scroll to ISI What is Wegovy ®?. This medicine is subject to additional monitoring. 0. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. WEGOVY semaglutide injection, for subcutaneous use Initial U. 2021. In studies, Zepbound has led to a 21% weight loss in adults using the highest dose, while Wegovy has led to about a 15% weight loss. These challenges include: Treatment disruptions: The shortage can disrupt treatment plans, leaving healthcare providers with limited options for prescribing Wegovy to their patients. 28 MB] Device/Product Name. WEGOVY® (semaglutide) injection, for subcutaneous use Initial U. 4 mg is an injectable prescription medicine that may help adults with obesity (BMI ≥30) or some adults with excess weight (BMI ≥27) These highlights do not include all the information needed to use WEGOVY safely and effectively. 4 mg weekly) Information Sheet What is Wegovy? Wegovy (semaglutide) is a prescription medicine that helps adults who are overweight or have obesity to manage their weight. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for FULL PRESCRIBING INFORMATION . Date registered. This will allow quick identification of new safety information. Signal Word Not required Hazard These highlights do not include all the information needed to use WEGOVY safely and effectively. wegovy - Free download as PDF File (. wegovy FlexTouch . 5 mL 1. • • RECENT MAJOR Narrator: Lisa is a patient ambassador for Novo Nordisk and has been compensated for her participation in this video. Aranesp® (darbepoetin alfa) injection, for intravenous or subcutaneous use . wegovy is a medicine for weight loss and weight maintenance that contains the active substance semaglutide. The Wegovy prescribing information sheet posted online was just updated this month. In patients with type 2 diabetes, monitor blood glucose prior to starting and during WEGOVY treatment (2. Consider treatment response and tolerability when selecting the maintenance dose This information from Lexicomp explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Ozempic (0. 5 mg once weekly. Ministry of Health - Pharmaceutical, Laboratory & Blood Services Division Subject: Information sheet for public input into B. Approval: 2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. Currently Wegovy ® (semaglutide) is available to patients 12 years of age and above. Obesity. To ensure you receive the information that meets your needs, please tell us whether you are: I am a member of the public based in GB → I am a patient prescribed Wegovy ® in GB → Semaglutide (Wegovy) is a type of medicine that can be used for aiding weight loss in adults and children over 12 years. Wegovy™ solution should be inspected visually prior to each injection and should be clear, colourless, and contain no particles. If you have any questions about your prescription please contact your prescriber. 5 September 2024. 25 mg once a week, and you will gradually increase your dose every four weeks. Wegovy ® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. 25 March 2022. It is now 43 pages. Individual results may vary. In people who have kidney problems, diarrhea, nausea, and There may be new information. Unlike all other GLP-1 analogs, Semaglutide is 94% identical to the natural endogenous GLP-1. 2020; 28:1050-1061. 5 mg FlexTouch® solution for injection in pre-filled pen . In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. In clinical trials, Wegovy users achieved an average weight loss of 14. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight Please see additional Important Safety Information throughout. Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m 2). Prescribing Information. Wegovy® is marketed and indicated for obesity. 7 mg FlexTouch ® solution for injection in pre-filled pen Highlights of the Article. Wegovy ® 0. The information referred to may not comply with Australian regulatory requirements. In SELECT, the Cardiovascular Outcomes Trial (CVOT) , 2656 (30%) Wegovy ®-treated patients were between 65 and 74 years of age, and 703 (8. It is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. Renewal PA requests require the member to be taking an appropriate maintenance dose, as outlined in the Wegovy prescribing information. See full prescribing information for RYBELSUS. to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. When you join WeGoTogether ®, you can be paired with a Health Coach who is dedicated to supporting your progress through calls, texts, and emails. See full prescribing information for MOUNJARO. WEGOVY® (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity: WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. 5 mg solution for injection in pre-filled pen . See full prescribing information for WEGOVY. Administer Wegovy™ subcutaneously in the abdomen, thigh, or upper arm. Week 1 to week 4: 0. Wegovy® works by causing you to feel fuller and less hungry. Change (i. 9% over 68 weeks, significantly higher than the 2. If Saxenda ® was exposed to non-refrigerated temperatures (any temperature above 46°F), the product must be used or discarded within 30 days. 1. pdf), Text File (. 25 mg FlexTouch® solution for injection in pre-filled pen . Scroll to ISI What is Ozempic ®?. It may have been superseded. 17 KB] Device/Product Name. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. Please see additional Important Safety Information throughout. Continue reading Scroll to ISI What is Wegovy ®?. 7 mg or 2. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for complete boxed warning. Ozempic® is marketed and indicated for type 2 diabetes. 5 mg, and 1 mg new safety information. [1-2] Semaglutide was initially approved as a treatment for type 2 diabetes, but studies have found that GLP-1 drugs At PrintFriendly. These highlights do not include all the information needed to use WEGOVY safely and effectively. Approval: 2017 See full prescribing information for complete boxed warning. The healthcare professional area contains promotional content and includes links to the prescribing information and adverse event reporting information. 4 mg Prescribing Information. I am a member of the public based in GB →. See full prescribing information for complete boxed warning. Tell your health care professional if you have any Suitable for prescribing in primary care following recommendation or initiation by a specialist. 25 mg once These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. 5 mg, 1 mg, or 2 mg is an injectable prescription medicine used:. Ozempic ® (semaglutide) injection 0. Subscribe to updates; Contact us; Facebook (Twitter) Youtube Wegovy (semaglutide) injection 2. C. Further information relevant to the Australian environment is available from Novo Nordisk (Australia) or via What is the most important information I should know about Wegovy®? (cont’d) Wegovy® may cause serious side effects, including: (cont'd) •Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine were randomized to receive either Wegovy™ (reduced calorie meal plan and increased physical activity) or placebo (reduced calorie meal plan and increased physical activity only), and evaluated over a 68-week period. Wegovy® FlexTouch® Consumer Medicine Information 1 Wegovy® FlexTouch® Consumer Medicine Information (CMI) summary The full CMI on the next page has more details. 4 mg (recommended) or 1. WEGOVY (semaglutide) injection, for subcutaneous use . Attachment Product Information for Wegovy [PDF, 1018. Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. Approval: 2017 . Please report side effects. solution for injection in pre-filled pen . WARNING: ESAs INCREASE THE RISK OF DEATH, Wegovy Prescribing Information. MOUNJARO® (tirzepatide) Injection, for subcutaneous use Initial U. 4 mg is indicated in combination with a reduced calorie diet and increased physical activity:. Initiate Wegovy with a dose of 0. 02 KB] Attachment Product Information for Wegovy [Word, 903. Important Safety Information What is the most important information I should know about Wegovy ®? Wegovy B. Wegovy ® Semaglutide . 25 or 0. 5 mg/0. 1)]: • 230 kg/m or greater (obesity) or These highlights do not include all the information needed to use WEGOVY ® safely and effectively. The WEGOVY pen is for subcutaneous (under the skin) use only. AusPAR Date. See full prescribing information for WEGOVY®. 8 months). [1] The active ingredient in Wegovy® is semaglutide, a glucagon-like peptide 1 receptor agonist that is more commonly known as a GLP-1 medication. NAME OF THE MEDICINAL PRODUCT . If needed, storage between 46°F and 86°F (8°C and 30°C) is permissible for up to 28 days. PART I: HEALTH PROFESSIONAL INFORMATION . What is the most important information I should know about WEGOVY? WEGOVY may cause serious side effects, including: • Possible thyroid tumors, including cancer. 25 mg solution for injection in pre-filled pen . 4 weekly. Instructions for use Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. In other words, Wegovy is a high-dose injectable Semaglutide, like Ozempic, that is administered weekly. Read Important Safety and Prescribing Info, including Boxed Warning. 4 mg once-weekly dose, the dose can Wegovy is administered by a weekly subcutaneous (SC) injection. It is available as an injection. See full prescribing information for OZEMPIC. Wegovy® and Ozempic® both contain the same active ingredient, semaglutide. WEGOVY (semaglutide) injection, for subcutaneous use Initial U. Users This guide will help you: Learn how to use your pen Understand the dosing schedule Know what to expect Access support and savings Your next step begins here These highlights do not include all the information needed to use WEGOVY safely and effectively. 25 mg, 0. WARNING: RISK OF THYROID C-CELL TUMORS . OZEMPIC® (semaglutide) injection, for subcutaneous use Initial U. Approval: 2022 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. 5 mL 1 mg/0. In rodents, semaglutide causes thyroid C-cell tumors Indications and Usage. Talk to your These highlights do not include all the information needed to use WEGOVY safely and effectively. Wilding JP, Batterham R, Calanna S, et al. 5 MG/DOSE); Ozempic (1 MG/DOSE); Ozempic (2 MG/DOSE); Rybelsus; Wegovy Brand Names: Canada Ozempic, Mounjaro, Wegovy and Zepbound can all lead to long-term weight loss, but only Wegovy and Zepbound are approved by the FDA for this use. You should store Wegovy ® in the refrigerator. • 1. Approval: 2017 Wegovy (Semaglutide 0. 4 mg is indicated for chronic weight management for adults with obesity and to reduce the risk of major adverse cardiovascular events in adults with obesity or overweight and cardiovascular disease. 25 mg once a week for four weeks, and then your Wegovy dose will increase every 4 weeks until you reach a maintenance dose of 1. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for Over 1 year and 4 months (68 weeks), a medical study looked at the effect and safety of Wegovy ® in adolescents with obesity. All medicines A-Z. Little or no specific monitoring required. . After a 3-month (12-week) screening period in which each participant received behavioral lifestyle therapy (counseling about healthy nutrition and physical activity), participants were then randomly assigned to two groups. 4 mg In addition to diet and exercise, to reduce risk of MACE (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CVD and either overweight or obesity, and for chronic weight management in patients with obesity ≥12 years and adults with overweight with at least one weight-related comorbidity. Kushner RF, Calanna S, Davies M, et al. to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight The most common side effects of Wegovy ® may include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. 4 mg is an injectable prescription medicine used for adults with obesity (BMI ≥30) or overweight (excess weight) (BMI ≥27) who also Wegovy® (semaglutide) injection 2. Information and fact sheets for patients and professionals. You can help by reporting any side effects you may get. Note: See the manufacturer’s prescribing information for complete details. Keep this Discover information, education and resources for Wegovy® (semaglutide 2. UK24SEMO00130 November 2024 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. 4 mg once weekly. Wegovy should Wegovy ® (semaglutide) injection 2. Scroll to ISI What is Wegovy ®?. S. 5% of patients who received placebo discontinued treatment as a result of gastrointestinal adverse events; Mean increases in resting heart rate of 1. Do not use Wegovy™ if particulate matter or colouration is seen. Brief prescribing document or information sheet may be required. com or phone 1800 668 626. It is not known if Wegovy ® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid What is Wegovy ®?. Prescribing Strength NDC Days Supply Dispense Quantity Recommended SIG 0. Wegovy Dosing Information. Dosing with Wegovy™ • Start Wegovy™ with a dose of 0. to reduce the risk of major adverse cardiovascular events (cardiovascular Indications and Usage. 25 mg injected subcutaneously once-weekly and follow the dose escalation schedule below to minimize gastrointestinal adverse reactions. Wegovy® 1 mg FlexTouch® solution for injection in pre-filled pen . As these instructions illustrate, the recommended storage temperature for Wegovy is between 36°F and 46°F (2°C and 8°C). ; Wegovy is generally safe for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. This is the Product Information that was approved with the submission described in this AusPAR. These highlights do not include all the information needed to use Aranesp safely and effectively. e. Each pack contains 4 Wegovy™ pens (one pen for each week). 4 mg, along with a reduced calorie diet and increased physical activity, is used to reduce the risk of major cardiovascular (CV) events such as death, heart attack, or stroke in This website has been developed by Novo Nordisk UK to provide information about: Wegovy ® (semaglutide injection) for Great Britain (GB). 5mg weekly; Week 9 to week 12: 1mg weekly; Week 13 to week 16: What to know about prescribing Wegovy™ How to prescribe once-weekly Wegovy™ Wegovy™ comes in 5 packs (one for each strength). ; Long-term results show that 77% of Wegovy users maintained a weight loss of 5% or more after two years, indicating its effectiveness for sustained weight management. 7 mg and 2. 4 September 2024. 0%) of Wegovy ® Attachment Product Information for Wegovy [Word, 1. Semaglutide (Wegovy, Novo Nordisk) is 'indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of ≥30 kg/m. The starting Wegovy dose is 0. Novo Nordisk Pharmaceuticals Pty Ltd. 1 INDICATIONS . 4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:. 25 mg (the dose you received in this kit) once per week in your first month • In your second month, increase your weekly dose to 0. Published. PharmaCare's drug coverage decision for semaglutide \(Wegovy\) Keywords These highlights do not include all the information needed to use WEGOVY safely and effectively. wegovy works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience The Wegovy ® starting dose is 0. com, you can edit, sign, share, and download the Wegovy Medication Information for Safe Use along with hundreds of thousands of other documents. This dose has shown efficacy in clinical trials and is the recommended maintenance dose per the prescribing information. · Your WEGOVY pen is for 1 time use only. OSHA Hazcom 2012 and Canadian WHMIS 2015 regulations. After 28 days, Wegovy should no longer be used, even if you put 2 Information about semaglutide . Suspected side effects reported with Wegovy are carefully evaluated and any necessary action taken to protect patients. Please click here for Prescribing Information, including Medication Guide. Wegovy should Wegovy ® contains the active ingredient semaglutide. • • RECENT MAJOR Revised: September 13, 2024 Wegovy Prior Authorization Form Fax completed form to MedStar Family Choice-MD 1-888-243-1790 or 410-933-2274 ALL requests must be accompanied by MEDICAL RECORDS to support the request. OZEMPIC (semaglutide) injection, for This guide will help you: Learn how to use your pen Understand the dosing schedule Know what to expect Access support and savings Your next step begins here Scroll to ISI What is Wegovy ®?. S Wegovy Fact Sheet UpdatedMar08 7 24 ore fa — 20% relative risk reduction RRR 1 5% absolute ARR * in MACE with Wegovy® as evaluated patients overweight or obesity and to reduce the of major cardiovascular events such death heart Up to date, approved and regulated prescribing and patient information for licensed medicines. and it is advisable to check with local pharmacies or healthcare providers for accurate pricing information. 2 beats per minute from baseline were observed with patients taking Wegovy ® Cardiovascular Risk Reduction . What is Wegovy®? Wegovy® (semaglutide) injection 2. • • RECENT MAJOR Refer to Instructions for Use within the Prescribing Information for how to use the Wegovy® pen. Costing information Based on the NICE Resource Impact Template for NICE TA875, the estimated cost of implementing this guidance is HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. Initiate at 0. Weeks 5 through 8 = 0. • • RECENT MAJOR Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. Wilding JP, Batterham R, et al. Please see the full Prescribing Information for . • Wegovy-pi-v2. Denmark: Wegovy was made available in Denmark, and all dose strengths were accessible since a specific time. Novo Nordisk told Atlanta News First Investigates, “Although Wegovy and Ozempic® both contain semaglutide, they are different products with different Wegovy ® comes in 5 different dose strengths, which are injected under the skin. See full prescribing information for Aranesp. 1 INDICATIONS AND USAGE WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight WEGOVY is an injectable prescription medicine that may help adults and children aged 12 years and older with obesity, or some adults with excess weight (overweight) who also have weight WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal Read Important Safety and Prescribing Info, including Boxed Warning. Wegovy ® (semaglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass Wegovy is administered once weekly at any time of the day, with or without meals. Find out side effects, medicine names, dosages and uses. Serious Warnings and Precautions The effect of Wegovy ® 2. Click here for Prescribing Information, including Boxed Warning, for Wegovy™. This Vaccine Information Fact Sheet contains information to help you understand the risks and benefits of COMIRNATY (COVID-19 Vaccine, mRNA),the Pfizer-BioNTech COVID-19 Vaccine, and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent, which you may receive because there is currently a pandemic of COVID-19. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZEMPIC® safely and effectively. In studies with rodents, Wegovy™ and medicines that work like Wegovy™ caused thyroid tumors, including thyroid cancer. txt) or read online for free. This medicine is new or being used differently. Wegovy is to be injected subcutaneously in the abdomen, in the thigh or in the upper arm. 0%) Wegovy ®-treated patients were between 65 and 74 years of age and 23 (1%) were ≥ 75 years of age. The injection site can be changed without dose adjustment. 7 mg solution for injection These highlights do not include all the information needed to use WEGOVY safely and effectively. If needed, however, Wegovy ® can be kept outside of the refrigerator between 46 °F to 86 °F for Indications and Usage. Approval: 2001 . Label elements Hazard pictogram(s) None required under U. Wegovy 1 mg solution for injection in pre-filled pen . The injection site Wegovy ® (semaglutide injection) Product Monograph Page 4 of 64 . Created Date: 12/13/2023 10:35:37 PM The Department of Health and Social Care have produced some public facing information on accessing semaglutide for weight loss: Accessing Wegovy for weight loss: Everything you need to know. It belongs to a group of drugs that copy a hormone in your body to help control appetite and how much food you eat. Week 17 and onward = 2. Includes: indications, dosage, adverse reactions and pharmacology. 5 mg • In your third month, increase your weekly dose to 1 mg • In your fourth month, increase your weekly dose to 1. For any product related queries, please contact Novo Nordisk Medical Information on aunrccc@novonordisk. If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks. If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks; The maintenance dose of Wegovy ® in adults is either 2. Gastrointestinal disorders were the most frequent adverse events with Wegovy ® (62% vs 42% with placebo); 2. Weeks 13 through 16 = 1. 7-clean Page 1 of 29 AusPAR - Wegovy - semaglutide - PM-2021-00612-1-5 - Novo Nordisk Pty Ltd Date of Finalisation 4 September 2024. Wegovy ® 1. Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, works by mimicking natural hormones that regulate appetite and digestion, making it a For complete instructions with diagrams on how to use Wegovy, see Instructions for Wegovy Use. • Important Safety Information. This comprehensive guide provides important information you need to know about prescribing Wegovy ®. Do not use Wegovy™ if particulate matter or colouration Wegovy is administered once weekly at any time of the day, with or without meals. The 0. PAY $25 *Eligibility and restrictions apply. (Wegovy). 1 . If patients do not tolerate the maintenance 2. Decision date. Search emc: Enter medicine name or company To ensure safe and effective use, emc and the pharmaceutical companies who provide information to this site, encourage reporting of suspected side effects to medicines, vaccines and medical device In studies with mice and rats, semaglutide (the active ingredient in Wegovy® and Ozempic®) caused thyroid tumors, including thyroid cancer. Your health care provider can select either 1. Recommended Dosage in Pediatric Patients Aged 12 Years and Older Dosage Initiation and Escalation Initiate WEGOVY according to the dosage escalation schedule in Table 2 to minimize gastrointestinal adverse reactions . semaglutide . It acts in the same way as GLP-1 (a natural hormone in the body) and, among other things, appears to regulate appetite by increasing a person Count on your Health Coach. Wegovy. 7 mg solution for injection See full prescribing information for WEGOVY. Wegovy: Start with 0. Sponsor. Tell your healthcare See the Wegovy ® Prescribing Information for details. Click here ®for Prescribing Information, including Boxed Warning, for Saxenda (liraglutide) injection 3 mg. Novo Nordisk Inc. Wegovy® is an injectable prescription drug that is FDA-approved and clinically proven to help with weight loss. The starting dose is 0. 7 mg/ 0. It has the smallest size and Please see additional Important Safety Information throughout. Wegovy ® (semaglutide) injection 2. Below is an example of a dosing schedule. Package leaflet: Information for the patient . 31 March 2021. Wegovy is administered once weekly at any time of the day, with or without meals. 1 1 1 2-6 2 3 4 with Overweight or Obesity 5 6 3 3 1 1. Search the Exchange To access the Prescribing Information for Novo Nordisk products, please explore our product page. This information does not replace talking to your healthcare provider about your medical condition or treatment. It is similar to a natural hormone called glucagon-like peptide-1 (GLP-1) that is released from the intestine after a meal. 4 mg for your maintenance dose. 1 INDICATIONS AND USAGE WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of [see Dosage and Administration (2. HIGHLIGHTS OF PRESCRIBING INFORMATION . If needed, prior to cap removal, the pen can be kept from 8°C to 30°C (46°F to 86°F) up to 28 days. 7 mg • n I your fifth month, you’ll increase your weekly dose to 2. Wegovy Recommended Dosage. Refer to FDA-approved Prescribing Information for final marketed products with regard to special storage, handling and administration requirements in the clinical setting. 75 mL 0169-4525-14 0169-4505-14 These highlights do not include all the information needed to use MOUNJARO safely and effectively. Inject subcutaneously in the abdomen, thigh or upper arm (2. Approval: 2017 WARNING: RISK OF THYROID C−CELL TUMORS See full prescribing information for Abbreviated prescribing information . Wegovy 1. Wegovy ® (semaglutide injection) is wegovy is used in addition to diet and physical activity to reduce the risk of serious heart issues (heart-related death, heart attacks, strokes) in adults with a history of heart disease (like a Wegovy-pi-v0. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using Wegovy® FlexTouch®. 25mg weekly; Week 5 to week 8: 0. Wegovy Injections are similar to Ozempic injections except that the dose of Semaglutide administered is high when Wegovy is used. I continued to diet and lose weight and gain it back. Subscribe to updates; Contact us; Facebook (Twitter) Youtube; Instagram; LinkedIn; Scroll to ISI What is Wegovy ®?. 2 (obesity), or For more information about using Wegovy, see the package leaflet or contact your healthcare provider. Approval: 2017 Scroll to ISI What is Wegovy ®?. If you are worried about using this medicine, speak to your doctor or pharmacist. 25 mg once weekly for 4 weeks. Wegovy™ (semaglutide) injection 2. 1). March 2024. It is not known if Wegovy® (semaglutide) will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Medicine information. Other information about Wegovy Wegovy received a marketing authorisation valid throughout the EU on 6 January 2022. Important Safety Information What are the possible side effects of Wegovy®? (cont’d) Wegovy® may cause serious side effects, including: (cont’d) • kidney problems (kidney failure). Wegovy 0. 25 to 2. References to depression and suicidal thoughts have not substantially changed. 5 mg, 1 mg, 1. These highlights do not include all the information needed to use RYBELSUS® safely and effectively. 3% of patients treated with Wegovy ® vs 1. Approval: 2017 WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. • • RECENT MAJOR In the Wegovy ® phase 3a weight management clinical trials, 233 (9. Wegovy® should be used along with a reduced calorie diet and increased physical activity. OZEMPIC(semaglutide) injection, for subcutaneous use Initial U. Store the Wegovy single-dose pen in the refrigerator from 2°C to 8°C (36°F to 46°F). Read about dosing, administration, pen storage and get details on benefits FULL PRESCRIBING INFORMATION . Semaglutide 2. Plainsboro, NJ. Semaglutide. For the most up to date information, consult the summary of product characteristics For information on Bedfordshire and Luton Joint Prescribing Committee (JPC) recommendations on Wegovy package insert / prescribing information for healthcare professionals. Once-weekly semaglutide in adults with overweight or obesity. Initial U. Active ingredients. 4% loss in the placebo group. Healthcare professionals are asked to report any suspected adverse reactions. What is the most important information I HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OZEMPIC® safely and effectively. It is not known if Wegovy ® is safe and effective for use in children under 12 years of age. The Wegovy shortage poses significant challenges for healthcare providers trying to manage their patients' weight loss and health. rotate) the site of injection for each administration. (4). Wegovy ® works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry and experience less craving for food Weight Management,Adults,Wegovy is indicated as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of,Equal to or greater than 30 kg/m2 (obesity), or,Equal to or greater than 27 kg/m2 to less than 30 kg This leaflet provides important information about using Wegovy® FlexTouch®. Please talk with your doctor to find out your specific dosing schedule. 3. Cancel Contact us. Marketing authorisation indication . 2. RYBELSUS (semaglutide) tablets, for oral use Initial U. How does Wegovy® work? Wegovy® is similar to a natural hormone called glucagonlike peptide- -1 (GLP-1) that is released from the intestine after a meal. See full prescribing information for OZEMPIC ®. On average, adults were in the trial for 3. They all advised the same thing: diet and exercise. AU24NNM00004 | July 2024. 25 mg per week; Escalate the patient’s Wegovy ® dose every 4 weeks; Please refer to the Prescribing Information for full dosing information; If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY® safely and effectively. The injection site Wegovy™ solution should be inspected visually prior to each injection and should be clear, colourless, and contain no particles. It must be completed by a prescriber for coverage through the TRICARE pharmacy program. NovoSeven ® RT Ozempic ® Rebinyn ® Rivfloza ® Rybelsus ® Saxenda ® Sogroya ® Tresiba ® Tretten ® Vagifem ® Victoza ® Wegovy Saxenda ® can be used as long as the product has not been exposed to temperatures below 36°F or above 86°F. 4 mg Prescribing Information For more information about the dose escalation schedule for Wegovy ®, please see the Prescribing Information. WARNING: RISK OF THYROID C -CELL TUMORS . Our platform helps you seamlessly edit PDFs and other documents online. Prescribing Information Sheet, November 2020 This document provides general prescribing information on the use of Semaglutide. Weeks 9 through 12 = 1 mg once weekly. This video is based on the Instructions for Use that come with your Wegovy ® pen. All study participants also received standard of care for their The Prior Authorization Fax Cover Sheet is available on the Forms page of the Portal for prescribers or their designee submitting the forms and documentation by fax. How does Wegovy work? The active substance in Wegovy, semaglutide, is a ‘GLP-1 receptor agonist’. It is not known if Wegovy™ will cause thyroid tumors or a type of thyroid cancer called Administer WEGOVY once weekly as an adjunct to diet and increased physical activity, on the same day each week, at any time of day, with or without meals (2. Subscribe to updates; Contact us; Facebook (Twitter) Youtube new safety information. Saxenda ® should be inspected for changes such as precipitation, or change in color or clarity that may indicate a Suitable for prescribing in primary care following recommendation or initiation by a specialist. PharmaCare Drug Information Sheet for semaglutide (Wegovy) Author: B. Wegovy® 0. It has gained attention for its ability to support lasting weight loss when combined with a healthy diet and regular exercise. 5 mL 0. Lisa: All my life, my health care providers told me I needed to lose weight. If needed, however, Wegovy ® can be kept outside of the refrigerator between 46°F to 86°F for These highlights do not include all the information needed to use WEGOVY safely and effectively. Wegovy has become one of the most popular FDA-approved treatments for weight management. 4 mg once weekly on the risk of major cardiovascular events such as death, heart attack, or stroke was studied in adults with known heart disease and either obesity or overweight compared with those on placebo (an inactive injection). 4mg) for overweight and obesity. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use WEGOVY safely and effectively. WEGOVY ® (semaglutide) injection 2. along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes; to This video is based on the Instructions for Use that come with your Wegovy ® pen. 7 mg once weekly. Evaluation commenced. Authorised Prescriber; Office of Drug Control; State and territory contacts; Connect with us. 1 September 2022. 25 mg/0. As for all medicines, data on the use of Wegovy are continuously monitored. wfr knvm iewhd lluxs hkcslf qdq ckaii jjqu slsdry atz